<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738905</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00004204</org_study_id>
    <nct_id>NCT02738905</nct_id>
  </id_info>
  <brief_title>Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease</brief_title>
  <official_title>Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jason Stubbs, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide
      (TMAO) levels in patients with end-stage renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will undergo 3 study visits: baseline, day 7 (immediately post-therapy),
      day 21 (2 weeks post-therapy). All participants will provide blood and stool samples at each
      visit.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum TMAO levels</measure>
    <time_frame>Change from Baseline to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum TMAO levels</measure>
    <time_frame>Change from Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal bacterial species</measure>
    <time_frame>Change from Baseline to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal bacterial colony numbers</measure>
    <time_frame>Change from Baseline to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal bacterial species</measure>
    <time_frame>Change from Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal bacterial colony numbers</measure>
    <time_frame>Change from Baseline to Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug for a period of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>One 550 mg tablet taken orally two times a day.</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>XIFAXAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of end-stage renal disease

          -  Receiving chronic intermittent hemodialysis

        Exclusion Criteria:

          -  Patients with less advanced kidney disease

          -  Inability or unwillingness to provide informed consent

          -  Patients who may be pregnant

          -  Hemodynamically unstable patients

          -  Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease

          -  Patients with ongoing or recent infection and those with history of C-diff infection

          -  Patients with abnormal bowel structure secondary to surgical or anatomic variations

          -  Patients on certain medications, including immunosuppressants, antidiarrheal agents,
             or recent (within the last 2 months) use of antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Stubbs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westwood Dialysis Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Jason Stubbs, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

